30-Second Takeaway
- ACCEPT 3.0-UK **AUC 0.77** outperforms exacerbation history for predicting COPD exacerbations and is well calibrated after recalibration.
Week ending June 27, 2026
Phenotypes, trajectories, and prediction tools to personalize respiratory care
Two ARF phenotypes predict prognosis and APP response
Two reproducible phenotypes were identified in non-intubated acute respiratory failure across three cohorts. Phenotype 2 had worse oxygenation, higher lactate, more coagulopathy, and higher 28-day intubation (56.7%) and mortality (22.0%) than Phenotype 1. Phenotype 1 patients derived the most benefit from prolonged awake prone positioning (significant interaction, adjusted p = 0.048). The authors provide two parsimonious prediction models for bedside phenotype assignment, but external implementation details are limited.
Rapid sPAP progression identifies high-risk SLE‑PAH subgroup
In 81 SLE‑PAH patients, four sPAP trajectories were derived; trajectory 4 showed high initial sPAP with rapid increase. Trajectory 4 independently predicted mortality with HR 8.843 after multivariable adjustment. Trajectory 4 correlated with higher inflammatory markers, shorter 6MWD, and greater right‑ventricular strain. Trajectory-based risk groups may inform closer monitoring and aggressive therapy in SLE‑PAH, pending broader validation.
Protocol: azithromycin maintenance versus placebo in young children with structural lung disease
This multicentre, double‑blind RCT will randomize 150 children (0–72 months) to azithromycin 10 mg/kg three times weekly or placebo for six winter months. Primary outcome is reduction in respiratory infections; secondary outcomes include lung function, symptoms, quality of life, and safety. The trial is powered to provide efficacy and safety data in a vulnerable pediatric population where current maintenance use lacks robust evidence.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.